Condition
Limb-Girdle Muscular Dystrophy, Type 2E
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
1 treatments under study, led by Srp9003
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Completed1
Terminated1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03652259Phase 1/2TerminatedPrimary
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
NCT03488784Completed
Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E
NCT03492346UnknownPrimary
Limb Girdle Muscular Dystrophy Type 2E Recruitment Study
Showing all 3 trials
Research Network
Common Treatments
- Srp90031
Active Sponsors
- Nationwide Children's Hospital1
- Lindsay Alfano1
- Sarepta Therapeutics, Inc.1
- Myonexus Therapeutics1
Top Investigators
Nationwide Children's Hospital
Nationwide Children's Hospital
Related Conditions
- Limbgirdle Muscular Dystrophy Type 2a1